X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (57) 57
index medicus (57) 57
female (45) 45
oncology (44) 44
continued tamoxifen (41) 41
breast cancer (39) 39
postmenopausal women (38) 38
breast neoplasms - drug therapy (33) 33
randomized-trial (33) 33
aromatase inhibitors (31) 31
tamoxifen (29) 29
cancer (26) 26
aromatase inhibitors - therapeutic use (21) 21
anastrozole (19) 19
postmenopause (19) 19
care and treatment (18) 18
letrozole (18) 18
quality-of-life (18) 18
tamoxifen - therapeutic use (18) 18
chemotherapy, adjuvant (16) 16
middle aged (15) 15
antineoplastic agents, hormonal - therapeutic use (14) 14
aromatase inhibitors - adverse effects (14) 14
exemestane (14) 14
bone-mineral density (13) 13
endocrine therapy (13) 13
hematology, oncology and palliative medicine (13) 13
treatment outcome (13) 13
aged (12) 12
drug therapy (12) 12
health aspects (12) 12
hematology (12) 12
research (12) 12
chemotherapy (11) 11
male (11) 11
medicine & public health (11) 11
risk factors (11) 11
therapy (11) 11
adjuvant endocrine therapy (10) 10
adjuvant treatment (10) 10
antineoplastic agents - therapeutic use (10) 10
antineoplastic agents, hormonal - adverse effects (10) 10
breast neoplasms - pathology (10) 10
aromatase inhibitors - administration & dosage (9) 9
disease-free survival (9) 9
early breast-cancer (9) 9
phase-iii (9) 9
intergroup exemestane (8) 8
prevention (8) 8
quality of life (8) 8
tamoxifen - adverse effects (8) 8
tamoxifen therapy (8) 8
adjuvant therapy (7) 7
adult (7) 7
analysis (7) 7
antineoplastic agents - adverse effects (7) 7
antineoplastic agents, hormonal - administration & dosage (7) 7
aromatase inhibitor (7) 7
continued standard chemotherapy (7) 7
development and progression (7) 7
early breast cancer (7) 7
stem-cell transplantation (7) 7
survival (7) 7
androstadienes - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
continued hospitalization (6) 6
double-blind (6) 6
early hospital discharge (6) 6
follow-up studies (6) 6
medicine, general & internal (6) 6
neoplasm staging (6) 6
neoplasms, hormone-dependent - drug therapy (6) 6
recurrence (6) 6
tamoxifen - administration & dosage (6) 6
women (6) 6
1st-line therapy (5) 5
abridged index medicus (5) 5
adjuvant (5) 5
androstadienes - adverse effects (5) 5
animals (5) 5
antineoplastic agents (5) 5
aromatase (5) 5
atac arimidex (5) 5
austrian breast (5) 5
breast neoplasms - mortality (5) 5
cancer research (5) 5
chemotherapy, adjuvant - methods (5) 5
child (5) 5
children (5) 5
clinical trials (5) 5
clinical trials as topic (5) 5
continued tobacco use (5) 5
drug administration schedule (5) 5
fever (5) 5
high-dose therapy (5) 5
hormonal-therapy (5) 5
internal medicine (5) 5
medicine, research & experimental (5) 5
menopause (5) 5
metastasis (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | SURVIVAL | PLUS DEXAMETHASONE | COMPLETE REMISSION | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, ISSN 2152-2650, 04/2014, Volume 14, Issue 2, pp. 148 - 154
We investigate the prognosis of multiple myeloma in 173 patients treated with high-dose melphalan and autologous transplantation in the era of old drugs. The... 
SURVIVAL | SINGLE | MANAGEMENT | COMPLETE REMISSION | Autologous transplantation | BONE-MARROW-TRANSPLANTATION | Multiple myeloma | Long-term results | RANDOMIZED-TRIAL | IMPACT | THERAPY | ONCOLOGY | High-dose melphalan | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY
Journal Article
Blood, ISSN 0006-4971, 02/2019, Volume 133, Issue 7, pp. 652 - 659
The treatment landscape for multiple myeloma has dramatically changed over the past decade with the introduction of several new classes of drugs, which are... 
DEXAMETHASONE | INDUCTION THERAPY | HIGH-DOSE THERAPY | BONE-MARROW-TRANSPLANTATION | CONSOLIDATION THERAPY | RANDOMIZED-TRIAL | CONTINUED STANDARD CHEMOTHERAPY | OPEN-LABEL | STEM-CELL TRANSPLANTATION | HEMATOLOGY | LENALIDOMIDE MAINTENANCE
Journal Article
Journal Article
BMC Cancer, ISSN 1471-2407, 07/2018, Volume 18, Issue 1, pp. 771 - 771
Journal Article
Expert Review of Hematology, ISSN 1747-4086, 02/2014, Volume 7, Issue 1, pp. 43 - 53
Induction therapy followed by intensification with ASCT is the standard of care in younger patients with multiple myeloma. Three-drug induction regimens... 
multiple myeloma | induction | thalidomide | new drugs | transplantation | lenalidomide | bortezomib | AUTOLOGOUS TRANSPLANTATION | RANDOMIZED-TRIAL | CONDITIONING REGIMENS | INTERGROUPE FRANCOPHONE | 200 MG/M | THALIDOMIDE PLUS DEXAMETHASONE | INDUCTION THERAPY | HIGH-DOSE THERAPY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2009, Volume 361, Issue 8, pp. 766 - 776
This study of adjuvant hormonal therapy in postmenopausal women with hormone-receptor–positive early breast cancer showed that disease-free survival was... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | EXEMESTANE | CONTINUED TAMOXIFEN | ADJUVANT ENDOCRINE THERAPY | RANDOMIZED-TRIAL | POSTMENOPAUSAL WOMEN | AROMATASE INHIBITORS | ANASTROZOLE | Aromatase Inhibitors - administration & dosage | Triazoles - administration & dosage | Triazoles - adverse effects | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Neoplasm Recurrence, Local - prevention & control | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Kaplan-Meier Estimate | Proportional Hazards Models | Fractures, Bone - epidemiology | Breast Neoplasms - drug therapy | Tamoxifen - administration & dosage | Incidence | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Postmenopause | Female | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Nitriles - adverse effects | Women | Care and treatment | Usage | Breast cancer | Tamoxifen | Comparative analysis | Health aspects | Drug therapy | Womens health | Cancer therapies | Index Medicus | Abridged Index Medicus | Hormonal | Breast Neoplasms | epidemiology | administration & dosage | Triazoles | Nitriles | Adjuvant | drug therapy | Antineoplastic Agents | Local | prevention & control | Aromatase Inhibitors | Chemotherapy | Fractures | adverse effects | Bone | Neoplasm Recurrence | Cancer and Oncology | Kaplan-Meiers Estimate | Cancer och onkologi
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 2011, Volume 12, Issue 6, pp. 407 - 411
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 5/2012, Volume 133, Issue 1, pp. 227 - 236
Journal Article